Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 640

1.

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D.

Cancer Treat Rev. 2016 Mar;44:42-50. doi: 10.1016/j.ctrv.2016.01.003. Epub 2016 Feb 4. Review.

PMID:
26866673
2.

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.

Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I.

Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1.

PMID:
26828788
3.

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Tamura T, Ohe Y.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):155-62. doi: 10.1016/j.ijrobp.2015.09.026. Epub 2015 Sep 26.

4.

Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China.

Shi J, Zhu J.

Clin Drug Investig. 2016 Jan;36(1):77-86. doi: 10.1007/s40261-015-0356-9.

PMID:
26563152
5.

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.

Daga H, Takeda K, Okada H, Miyazaki M, Ueda S, Kaneda H, Okamoto I, Yoh K, Goto K, Konishi K, Sarashina A, Tanaka T, Kaiser R, Nakagawa K.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1225-33. doi: 10.1007/s00280-015-2896-3. Epub 2015 Nov 11.

PMID:
26560486
6.

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.

Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group.

Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.

PMID:
26522337
7.

Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.

Fujimoto D, Shimizu R, Kato R, Sato Y, Kogo M, Ito J, Teraoka S, Otoshi T, Nagata K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Anticancer Res. 2015 Nov;35(11):6261-6.

PMID:
26504060
8.

Effects of Definitive Chemoradiotherapy on Respiratory Function Tests and Quality of Life Scores During Treatment of Lung Cancer.

Duman E, Yildirim M, Kaya V, Ozturk D, Inal A, Akarsu Z, Gunduz S, Yildiz M.

Asian Pac J Cancer Prev. 2015;16(15):6779-82.

9.

Predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall lung cancer patients in China: A retrospective institution analysis of 132 patients.

Cheng B, Cai XJ, Chen LY, Wang Z, Weng L, Li QL.

J Cancer Res Ther. 2015 Aug;11 Suppl 1:C84-8. doi: 10.4103/0973-1482.163849.

10.

Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer.

Gladkov O, Ramlau R, Serwatowski P, Milanowski J, Tomeczko J, Komarnitsky PB, Kramer D, Krzakowski MJ.

Anticancer Drugs. 2015 Nov;26(10):1061-8. doi: 10.1097/CAD.0000000000000281.

PMID:
26295868
11.

Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.

Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H.

Lung Cancer. 2015 Oct;90(1):71-7. doi: 10.1016/j.lungcan.2015.07.006. Epub 2015 Jul 26.

12.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.

Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6.

PMID:
26159065
13.

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

Xu JL, Jin B, Ren ZH, Lou YQ, Zhou ZR, Yang QZ, Han BH.

PLoS One. 2015 Jul 6;10(7):e0131278. doi: 10.1371/journal.pone.0131278. eCollection 2015. Review.

14.

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.

Ann Oncol. 2015 Sep;26(9):1877-83. doi: 10.1093/annonc/mdv276. Epub 2015 Jul 3.

PMID:
26141208
15.

Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies.

Lu S, Yu Y, Chen Z, Ye X, Li Z, Niu X.

Lung. 2015 Oct;193(5):805-14. doi: 10.1007/s00408-015-9758-y. Epub 2015 Jun 29. Review.

PMID:
26119960
16.

Rebuttal From Dr Li et al.

Li WW, Burgers JA, Klomp HM, Hartemink KJ.

Chest. 2015 Dec;148(6):1380-1. doi: 10.1378/chest.15-1197. No abstract available.

PMID:
26110719
17.

POINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? Yes.

Tanner NT, Silvestri GA.

Chest. 2015 Dec;148(6):1373-5. doi: 10.1378/chest.15-1194. No abstract available.

PMID:
26110373
18.

Radical Oncological Surgery and Adjuvan Therapy in Non- Small Cell Lung Cancer Patients over 70 years of Age.

Demirci NY, Ulger S, Yilmaz U, Aydogdu K, Yilmaz A, Erdogan Y.

Asian Pac J Cancer Prev. 2015;16(11):4711-4.

19.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y.

Ann Oncol. 2015 Sep;26(9):1883-9. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23.

PMID:
26105600
20.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G.

Lung Cancer. 2015 Aug;89(2):139-45. doi: 10.1016/j.lungcan.2015.05.016. Epub 2015 May 27.

PMID:
26059274
Items per page

Supplemental Content

Loading ...
Write to the Help Desk